Overall, our study provides an initial platform for further exploring the feasibility of RAGE-blocking strategies in BC patients, particularly when affected by obesity, pre-diabetes and/or diabetes. The gene discussed is AGER; the disease is obesity due to melanocortin 4 receptor deficiency.